Are You Ready To Go Beyond The Cutting Edge At BIO 2016?
Being the 2015 educational planning committee co-chair for BIO provided behind the scenes insights into what makes for a good industry session proposal at BIO. But beyond that I also learned how important it is for those interested in putting together an educational session for a conference to begin the planning process early. So when Bayer’s VP and Head of the company’s east coast innovation center, Chandra Ramanathan, Ph.D., and I...
Continue Reading..
What Does The Successful Killing Of The Pfizer Allergan Deal Mean?
When I wrote the opinion piece on the U.S. government’s successful killing of the planned Pfizer Allergan merger, it was on the heels of a March Editor’s Note on the current state of U.S. corporate taxes. There are those who argue that U.S. companies aren’t seeking to invert due to high U.S. tax rates. And while we can dispute the rationale behind why companies have been seeking to relocate outside the United States, what...
Continue Reading..
Evolving The Biopharma R&D Model — Improbable Players Are Changing The Game
At a recent conference* I overheard an executive comment that the clinical trial space remains one of the biggest bottlenecks to successful drug development. Sure, companies are developing much more sophisticated and targeted therapies. However, ...
Continue Reading..
Is U.S. Government Tactical Switch From Too Big To Fail To Too Big To Leave Constitutional?
In the March 2016 issue of Life Science Leader magazine, my Editor’s Note, The U.S. Tax Man Cometh, The U.S. Corporations Leaveth, referenced the Pfizer-Allergan merger as pretty much a done deal. Little did I know then that the U.S. government would stoop to implementing government policies more familiar to those living in the former U.S.S.R., than a country founded on freedom and famous for supporting free enterprise. While not losing...
Continue Reading..
Are You Committed To Being A Better Leader?
I recently cracked open Leadership Vertigo, a book by S. Max Brown and Tanveer Naseer. I was immediately enthralled when the authors hit me with this tidbit. “Gallup research has found that the top 25 percent of teams (i.e., the best managed) versus the bottom 25 percent in any workplace (i.e., the worst managed), have nearly 50 percent fewer accidents and 41 percent fewer quality defects.”
Continue Reading..
The Best Pharma Manufacturing Conference You’ve Never Heard Of
Thanks to Outsourced Pharma chief editor Louis Garguilo taking the lead on serving as host of Life Science Leader magazine’s annual CMO Leadership Awards celebration and reception in New York City, my time was suddenly freed up to explore for new educational opportunities. And while I will admit to being biased as to the quality of educational opportunities offered by our own Outsourced Pharma conferences, I recently got back from an event...
Continue Reading..
How PhRMA Is Adapting To The Industry’s New Reality
PhRMA held its 2016 annual meeting March 9 and 10 in Washington, D.C. This was the first annual meeting held under the new leadership regime of Stephen Ubl. Having spent more than 10 years as the president and CEO of the Advanced Medical Technology Association (AdvaMed), Ubl took the PhRMA helm just three days after former Turing Pharmaceutical CEO Martin Shkreli made national headlines with his drug-price increase antics.
Continue Reading..
R&D Leadership Summit Provides Ear-Opening Experience
Life Science Leader magazine and CNBC were the only two members of the media invited to attend the 6th Annual R&D Leadership (RDL) Summit (I will explain why this is significant in a moment). Produced by the Conference Forum with support from PRA Health Sciences, the event provides an extremely intimate opportunity for R&D executives to network and openly discuss some of the biopharmaceutical industry’s most controversial issues (e.
Continue Reading..
What Will Be The End Result Of Bullying Biopharma?
If as adults we could invisibly walk on school playgrounds during recess, we might hear the stock response recited when encountering a bully — ‘Sticks and stones may break my bones, but words will never hurt me.”
Continue Reading..
BIO CEO 2016 Educational Sessions Provide Enlightenment
During this year’s BIO CEO Conference (partially covered here), much of my time was spent in the educational sessions, which I would rank as some of the best I have seen at any conference — ever. For example ...
Continue Reading..
Rob Wright
Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL
This website uses cookies to ensure you get the best experience on our website. Learn more